Mikael Dolsten

Dr. Mikael Dolsten is President of Pfizer Worldwide Research and Development, advancing the company's scientific leadership in small molecule medicines, biotherapeutics and vaccines. A physician and scientist, he co-chairs the Portfolio Strategy and Investment Committee and is a member of the Pfizer Executive Leadership Team. Mikael oversees all research in the areas of Anti-infectives; Cardiovascular, Metabolic & Endocrine Diseases; Neuroscience; Oncology; Indications Discovery; Immunology & Autoimmunity; Inflammation & Remodelling; Orphan & Genetic Diseases; Centers for Therapeutic Innovation; Vaccine R&D; Neusentis; CovX; and Rinat. Prior to joining Pfizer in 2009, Mikael was Senior Vice President, Wyeth Inc., and President of Wyeth Research where he led scientists across the U.S., Europe and Asia. Before joining Wyeth, Mikael served as Executive Vice President at Boehringer Ingelheim, responsible for R&D in the U.S., Canada, Germany, Italy, Austria and Japan. His earlier career as a pharmaceutical research leader included positions with Astra-Zeneca, Pharmacia and Upjohn. Mikael earned his PhD in tumor immunology and M.D. from the University of Lund in Sweden. He studied virology and cell biology at the Weizmann Institute in Israel and has been appointed as Adjunct Professor in Immunology at the Medical Faculty in Lund. Mikael is a fellow of the New York Academy of Medicine and a governor of the New York Academy of Sciences. He serves on the Science and Regulatory Executive Committee of The Pharmaceutical Research and Manufacturers of America (PhRMA), and the PhRMA Foundation Board of Directors. Mikael has published several patents and approximately 150 articles in international journals with particular emphasis in molecular cell biology, immunology and oncology.